Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer.

ABSTRACT:

Objectives

This retrospective study evaluated the individual benefits of tislelizumab and surgery, as well as their synergistic effect on progression-free survival (PFS) and overall survival (OS) of stage II-III non-small cell lung cancer (NSCLC) patients.

Methods

From September 2019 to June 2022, all participants with potentially resectable NSCLC who received chemotherapy (C) or tislelizumab plus chemotherapy (T) were included in the study. Participants were categorized into four groups based on surgery or not (S or NS) and the utilization of tislelizumab (T or C). Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method and log-rank test, as well as Cox proportional hazards models.

Results

Compared to C, T was associated

SUBMITTER: Huang X 

PROVIDER: S-EPMC11365867 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature